|
|
Thomson Financial Business Description:
| The Group's principal activities are the development of new pharmaceutical technologies through pre-clinical and clinical trial stages, with the primary focus on the development of its drug MBP8298 for Multiple Sclerosis. The Group has also licensed a new platform technology, HYC750 involving a method for mobilizing hematopoetic cells in humans for use in the treatment of cancer therapy related side effects and other diseases. The technology has undergone certain pre-clinical testing, as well as preliminary human clinical trials. |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on BioMS Medical Corporation
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
